ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Cardiology · JAMA Cardiol · 2026-06-01

Post hoc analysis of a trial in 13,165 patients with type 2 diabetes and CVD: a 6-component cardiorenal composite occurred in 23.7% on tirzepatide vs 27.4% on dulaglutide (HR 0.84). GI adverse events were more common with tirzepatide (42.5% vs 35.9%).

Secondary analysisn = 13,165
Nissen et al. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial
Diabetes and endocrinology · Lancet Diabetes Endocrinol · 2026-05-11

Pre-specified exploratory analysis of SURPASS-CVOT (type 2 diabetes with atherosclerotic disease): tirzepatide cut major kidney events vs dulaglutide (6.0% vs 7.6%; HR 0.77) over median 4.0 years. Nausea, vomiting and diarrhoea were more common with tirzepatide.

Secondary analysisn = 13,165
Zoungas et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial
Rheumatology · Arthritis Rheumatol · 2026-03-28

Phase 3b trial in 271 adults with active psoriatic arthritis and overweight or obesity: ixekizumab plus tirzepatide vs ixekizumab alone more often achieved ACR50 with ≥10% weight loss at 36 weeks (31.7% vs 0.8%; P<0.001). ACR50 alone 33.5% vs 20.4%.

RCTn = 271
Merola et al. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.